Pulmonary rehabilitation in connective tissue disease-associated interstitial lung disease: A systematic review
Main Article Content
Keywords
Connective Tissue Disease, Lung Diseases, Interstitial, Therapeutics, pulmonary rehabilitation, Pulmonary Medicine, Respiratory Therapy
Abstract
Background and aim: Interstitial lung disease (ILD) is the major contributor to mortality in between chronic lung diseases. ILD originates from voluminous pathophysiological factors. One of the reasons is connective tissue diseases (CTD). According to experts, patients with CTD-ILD may have a stable disease activity and not need conventional treatment. Also, with pulmonary rehabilitation (PR), these patients may benefit from improving clinical outcomes and regression in mortality. However, the characteristics of these patients and whether they have stable disease activity in practice are not known. Methods: The systematic review was performed via the AI-powered tool with six databases to conduct literature research. The methodologic quality of the studies, risk of bias, and level of evidence were assessed. Results: According to the final four included studies PR benefit moderate levels of evidence for lung functions and diffusion capacity, functional capacity, quality of life, dyspnea severity, and fatigue level. However, there was limited evidence for respiratory, and peripheral muscle strength for CTD-ILD patients. Conclusions: The literature shows that the use of PR for CTD-ILDs wasn’t widespread. Our findings suggest that PR can be used in CTD-ILDs to recover clinical parameters like, lung functions, quality of life, dyspnea severity, and fatigue level. More comprehensive studies should be conducted to reveal the effect of the PR in the evidence-based frame.
References
2. Wytrychowski K, Hans-Wytrychowska A, Piesiak P, Majewska-Pulsakowska M, Rożek-Piechura K. Pulmonary rehabilitation in interstitial lung diseases: A review of the literature. Adv Clin Exp Med. 2020 Feb;29(2):257-264.
3. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet (London, England). 2022;400(10354):769-786. doi:10.1016/S0140-6736(22)01052-2
4. Olson A, Hartmann N, Patnaik P, et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv Ther. 2021;38:854-867.
5. Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021;59(6):709-740. doi:https://doi.org/10.1016/j.resinv.2021.04.011
6. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007;66(7):940-944.
7. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352. doi:10.1136/bmj.h6819
8. Şenel AS, Denizhan TK, Kızıltepe M, Kokoglu EO, Tutar N. Recurrent spontaneous pneumothorax under nintedanib treatment in interstitial lung disease associated with systemic sclerosis. Sarcoidosis, Vasc Diffus Lung Dis. 2023;40(4).
9. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1182-1200.
10. Tognolo L, Coraci D, Fioravanti A, et al. Clinical impact of balneotherapy and therapeutic exercise in rheumatic diseases: A lexical analysis and scoping review. Appl Sci. 2022;12(15):7379.
11. Valaas HL, Klokkerud M, Hildeskår J, et al. Rehabilitation goals described by patients with rheumatic and musculoskeletal diseases: content and attainment during the first year after rehabilitation. Disabil Rehabil. 2022;44(25):7947-7957.
12. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST.
13. Cavalheri V, Vainshelbaim B, Evans RA, da Fontourna FF, Lee A. Special considerations in conditions other than COPD. In: Pulmonary Rehabilitation. European Respiratory Society; 2021:145-64.
14. Wen Z, Chai Y. Effectiveness of resistance exercises in the treatment of rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2021;100(13).
15. Rochester CL, Alison JA, Carlin B, et al. Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2023;208(4):e7-e26. doi:10.1164/rccm.202306-1066ST
16. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society (vol 63, Suppl V, pg v1, 2008). Thorax. 2008;63(11):1029.
17. Gupta RS, Koteci A, Morgan A, George PM, Quint JK. Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review. BMJ Open Respir Res. 2023;10(1):e001291.
18. Singh SJ, Halpin DMG, Salvi S, Kirenga BJ, Mortimer K. Exercise and pulmonary rehabilitation for people with chronic lung disease in LMICs: challenges and opportunities. Lancet Respir Med. 2019;7(12):1002-1004.
19. Johnson N, Phillips M. Rayyan for systematic reviews. J Electron Resour Librariansh. 2018;30(1):46-48.
20. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-0399ST
21. Behr J, Bonella F, Frye BC, et al. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses S2k Guideline of the German Respiratory Society. Respiration. 2024 Sep 9:1-43. doi: 10.1159/000540856.
22. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727.
23. Burgers J, Everdingen J. [Evidence-based guideline development in the Netherlands: the EBRO platform]. Ned Tijdschr Geneeskd. 2004;148:2057-2059.
24. Bakker EWP, Verhagen AP, van Trijffel E, Lucas C, Koes BW. Spinal mechanical load as a risk factor for low back pain: a systematic review of prospective cohort studies. Spine (Phila Pa 1976). 2009;34(8):E281-E293.
25. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro scale for rating quality of randomized controlled trials. Phys Ther. 2003;83(8):713-721.
26. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi:10.1136/bmj.d5928
27. Sterne JAC, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
28. Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax. 2017;72(7):610-619.
29. de Alegria SG, Litrento PF, de Oliveira Farias I, Mafort TT, Lopes AJ. Can home rehabilitation impact impulse oscillometry and lung ultrasound findings in patients with scleroderma-associated interstitial lung disease? A pilot study. BMC Res Notes. 2022;15(1). doi:10.1186/s13104-022-06064-6
30. Antonioli CM, Bua G, Frigè A, et al. An individualized rehabilitation program in patients with systemic sclerosis may improve quality of life and hand mobility. Clin Rheumatol. 2009;28:159-165.
31. Yakut H, Özalevli S, Aktan R, Özgen Alpaydın A, Merih Birlik A, Can G. Effects of supervised exercise program and home exercise program in patients with systemic sclerosis: A randomized controlled trial. Int J Rheum Dis. 2021;24(9):1200-1212.
32. Dowman L, McDonald CF, Hill C, et al. The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial. BMC Pulm Med. 2013;13. doi:10.1186/1471-2466-13-8
33. Nikoletou D, Ster IC, Lech CY, et al. Comparison of high-intensity interval training versus moderate-intensity continuous training in pulmonary rehabilitation for interstitial lung disease: a randomised controlled pilot feasibility trial. BMJ Open. 2023;13(8):e066609. doi:10.1136/bmjopen-2022-066609
34. Beldner S, Rabinovich RV, Polatsch DB. Scleroderma of the hand: evaluation and treatment. J Am Acad Orthop Surg. 2020;28(16). doi: 10.5435/JAAOS-D-19-00547
35. Rochester CL, Vogiatzis I, Holland AE, et al. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373-1386. doi:10.1164/rccm.201510-1966ST
36. Spielmanns M, Gloeckl R, Schmoor C, et al. Effects on pulmonary rehabilitation in patients with COPD or ILD: A retrospective analysis of clinical and functional predictors with particular emphasis on gender. Respir Med. 2016;113:8-14. doi:https://doi.org/10.1016/j.rmed.2016.02.006
37. Dowman L, Hill CJ, May A, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021 Feb 1;2(2):CD006322. doi: 10.1002/14651858.CD006322.pub4.
38. Kesikburun B, Köseoğlu BF, Şahin A, Turgay M, Doğan A, Ayhan Öken Ö. The effects of respiratory muscle weakness and pulmonary involvement on functional status, fatigue and health related quality of life in patients with systemic sclerosis. Turkish J Rheumatol. 2015;30(2):116-123. doi:10.5606/ArchRheumatol.2015.5238
39. Arshad A, Rashid R, Benjamin K. The effect of disease activity on fat-free mass and resting energy expenditure in patients with rheumatoid arthritis versus noninflammatory arthropathies/soft tissue rheumatism. Mod Rheumatol. 2007;17(6):470-475.
40. Mochizuki T, Yano K, Ikari K, Okazaki K. Sarcopenia‐associated factors in Japanese patients with rheumatoid arthritis: A cross‐sectional study. Geriatr Gerontol Int. 2019;19(9):907-912.
41. Sciriha A, Lungaro-Mifsud S, Fsadni P, Scerri J, Montefort S. Pulmonary Rehabilitation in patients with Interstitial Lung Disease: The effects of a 12-week programme. Respir Med. 2019;146:49-56.
42. Garvey C. Interstitial lung disease and pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2010;30(3):141-146.
43. Ayyıldız A, Yılmaz F, Altındaş H, Çiftci S, Kuran B. Effects of Aerobic and Resistive Exercise on Muscle Measurements and Body Composition in Female Patients With Rheumatoid Arthritis. Am J Phys Med Rehabil. 2023;102(12).
44. Bartlett DB, Willis LH, Slentz CA, et al. Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study. Arthritis Res Ther. 2018;20:1-15.
45. Mittoo S, Frankel S, LeSage D, et al. Patient perspectives in OMERACT provide an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD). Curr Respir Med Rev. 2015;11(2):175-183.
46. Arora S. Updates in Management of Ctd-Ild. Arch Resp Res. 2024;3(004).
47. Yablonsky K, Sher Y. Rates of Anxiety and Depression in Interstitial Lung Disease by Diagnosis Category. In: TP13. TP013 Demographic, Psychosocial, and Clinical Correlates Of Pulmonary, Critical Care, and Lung Diseases.American Thoracic Society; 2021:A1554-A1554.
48. Liao J-Z, Zhu M, Luo F-M. The prevalence and risk factors for anxiety/depression in patients with connective tissue disease (CTD) associated interstitial lung diseases (ILDs). Published online 2022. doi: 10.21203/rs.3.rs-1477946/v1
49. Yakut H, Özalevli S, Birlik AM. Fatigue and its relationship with disease-related factors in patients with systemicsclerosis: A cross-sectional study. Turkish J Med Sci. 2021;51(2):530-539.
50. Veit T, Barnikel M, Kneidinger N, et al. Clinical Impact of Physical Activity and Cough on Disease Progression in Fibrotic Interstitial Lung Disease. J Clin Med. 2023;12(11). doi:10.3390/jcm12113787
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
